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Abstract 
 
Background: Myasthenia gravis (MG) is an acetylcholine receptor antibody-
mediated disease targeting the neuromuscular junction resulting in fatigable 
muscle weakness. A number of reports have suggested a high prevalence of 
psychiatric symptoms amongst MG patients. Approximately 10% of MG 
subjects are found to have an associated thymoma and despite 
thymomectomy, the MG persists. The presence of thymoma may lead to other 
antibody-mediated neuropsychiatric manifestations including limbic 
encephalitis. We hypothesized that the prevalence of neuropsychiatric 
symptoms may be higher in MG subjects with thymoma-associated MG when 
compared with those who have non-thymoma MG. 
 
Aims: This study aims to compare the prevalence of neuropsychiatric 
symptoms in a South African population of non-thymoma MG and thymoma-
associated MG. 
 
Method: A blinded cross-sectional psychiatric evaluation was performed on 
thirty adults with MG. Twenty-one had non-thymoma MG and nine had 
thymoma-associated MG. The severity of MG in each participant was 
assessed by a dedicated MG clinic using the quantified myasthenia gravis 
score (QMGS). The age at symptom diagnosis, years of symptoms before 
and on treatment, timing of thymectomy or thymomectomy and current 
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Neuropsychiatric assessments included: a self-reported 15-item Quality of Life 
Scale; the Beck Depression Inventory (BDI-II); the Hamilton Anxiety Rating 
Scale (HAM-A); the Young Mania Rating Scale (YMRS) and the Brief 
Psychiatric Rating Scale (BPRS).  
 
Results: Overall, high rates of moderate to severe depression(33.3%) and 
anxiety(33.3%)symptoms were present across both groups. However, there 
was no significant difference in the frequency and nature of neuropsychiatric 
symptoms between thymoma and non-thymoma MG groups. High scores on 
the BDI-II correlatedpositively with disease severity (p=0.008) as measured by 
the QMGS and presence of respiratory symptoms and tended to occur in 
those with a longer duration of illness (p=0.08). The presence of moderate to 
severe anxiety symptoms was associated with a longer disease duration 
(p=0.035) and showed significant overlap with symptoms of depression 
(p=0.001). There was a tendency towards suicidality (p=0.07) and need for 
psychiatric referral (p=0.08) associated with MG symptoms onset at a 
younger age. 
 
Conclusion: Neuropsychiatric symptoms such as depression and anxiety are 
prevalent in this MG population and necessitate identification and subsequent 
psychiatric referral. No differences could be detected in the prevalence of 
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Abstract 
 
Background: Myasthenia Gravis (MG) is an autoimmune disease affecting the 
nicotinic acetylcholine receptors (nAchRs) of the neuromuscular junction 
which manifests as fatigability and fluctuating muscle weakness.  MG is 
thought to exclusively involve the “peripheral” nervous system, yet for several 
decades, physicians have argued that the brain may be affected by MG.   
 
Approximately 10% of patients with MG are associated with the presence of 
thymoma. Thymoma patients may have several paraneoplastic syndromes 
including limbic encephalitis (Evoli, 2002), which involves the brain. In this 
study we wish to explore the prevalence of neuropsychiatric symptoms in MG 
and hypothesize that these symptoms may be higher in thymoma-MG 
compared to subjects without thymoma. 
 
Aims: To compare the prevalence and nature of neuropsychiatric symptoms in 
a sample of patients with thymoma-MG with those of MG without thymoma. 
 
Method: This is a cross-sectional pilot study. A randomly selected sample 
comprising of 10 patients with thymoma-MG and 20 patients with non-
thymoma MG attending the Groote Schuur Hospital (GSH) Myasthenia Gravis 
Clinic in Cape Town will be studied. As thymoma-MG is rare, the thymoma 
sample will be randomly selected from the existing UCT/GSH MG clinic 
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Each patient will be assessed by the Neurology team as part of his or her 
routine clinic visit. Patients who agree to take part in the study will provide 
written informed consent and complete a self reported Flanagan 15 item 
Quality of Life Scale (QOL) prior to the psychiatric assessment. The 
psychiatric assessment will be performed in a private consultation room by a 
mental health professional in the GSH Neurology ward. Demographic data 
and a brief medical history will be obtained. The psychiatric interview will be 
semi-structured and includes the following rating scales: Beck’s Depression 
Inventory (BDI-II); Brief Psychiatric Rating Scale (BPRS); Hamilton Anxiety 
Rating Scale (HARS) and the Young Mania Rating Scale (YMRS).  
 
Results: The data will be pooled and analyzed with the assistance of a trained 
statistician employed by the University of Cape Town. The results will be 
presented to both the Dept. of Psychiatry and the Division of Neurology at the 
University of Cape Town. The study will be submitted for publication in a peer-
reviewed journal. 
 
Conclusion: Should our hypothesis prove correct, we will use the evidence to 
support the implementation of adequate psychiatric screening services in 
existing MG clinics. Should the findings reveal that the prevalence of 
neuropsychiatric symptoms in thymoma-associated is higher than non-
thymoma MG, a larger controlled study with further research into the 
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Study Objectives: 
 
• To determine the prevalence of mood, anxiety and psychotic symptoms 
in a representative sample of the MG population attending the GSH 
MG clinic. 
• To compare the prevalence of neuropsychiatric symptoms i.e. 
disturbance in mood, perception, thought and behaviour in thymoma-
MG vs. MG without thymoma. 
• To compare the mean QOL scores of MG patients with those of 




1) To establish the prevalence of neuropsychiatric symptoms in a 
representative sample of MG patients attending a dedicated quaternary 
level clinic. 
2) To compare the nature and prevalence of neuropsychiatric symptoms 




1.1 Myasthenia Gravis 
 
Myasthenia Gravis (MG) is a chronic, potentially debilitating autoimmune 
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junction (NMJ) of skeletal muscle. The majority of cases with MG are “sero-
positive” and have pathogenic antibodies to the acetylcholine receptor (AChR) 
directed at the alpha-1 subunit of the nAChR. The affected individual can 
present at any age. The condition is characterized by muscle weakness and 
fatigability which may fluctuate during the course of the day and is typically 
worsened by exertion (Fauci, 1998). Approximately 10% of MG cases are 
associated with thymoma, from here known as thymoma-MG (Evoli, 2002).  
MG without thymoma will be referred to as MG. 
 
MG is thought to be limited to the peripheral nervous system. As early as the 
19th century, a number of physicians have argued that MG involves the central 
nervous system (CNS) (Keesey 1999). Evidence of central cholinergic 
involvement in MG has been suggested following several observations. 
Firstly, EEG changes have been noted in several patients with MG, not 
accounted for by epilepsy or other clinical parameters e.g. medication. Diffuse 
slow and focal slow abnormalities were observed in 14 of 118 patients with 
MG (Tartara, 1982). Secondly, altered rapid eye movement (REM) sleep has 
been observed in patients with MG, suggesting central involvement. Of a 
sample of ten patients with MG, all exhibited signs of disturbed REM sleep. 
One member of this sample was subsequently treated with prednisone and 
his REM sleep returned to normal limits (Papazian 1976). Thirdly, Fotiou 
(2000) reports that abnormal pattern-reversal visually evoked potentials have 
been demonstrated in patients with MG suggesting a disturbance of CNS 
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1.2 Psychiatric symptoms in Myasthenia Gravis 
 
Central involvement of MG has been further argued in both psychiatric and 
psychological literature, the results of which, remain inconsistent and are 
criticized for being outdated and making use of unsound methodology. In a 
study by Rohr (1992), 20% of 200 study sample patients with MG were 
diagnosed as having a psychiatric illness prior to the diagnosis of MG with 
symptoms and signs of disturbed perception, thought content, mood or 
behaviour. More recently, Sitek et al (2009) administered a 
neuropsychological battery of tests to 33 individuals with MG and 30 healthy 
controls. They were unable to demonstrate CNS deficit as cognitive tasks 
independent of motor or visual function remained unimpaired. Although an 
incidence of axis I and axis II disorders reached as high as 51% in some 
studies, a number of authors have argued the validity of these results. Their 
main concerns being that somatic symptoms may interfere with the correct 
assessment of mood, rating scales were non-specific, sample sizes were 
small and structured clinical interviews were lacking (Kulaksizogli, 2007). Paul 
et al. (2000) investigated the severity of mood, self evaluative and vegetative 
symptoms of depression in patients with MG. They found that the prevalence 
of depression was statistically significant only in the assessment of vegetative 
symptoms compared with those in the control group. They recommend that 
patients with “neuro-immune” disease are assessed using specific scales for 
the different dimensions of depression i.e. the assessment of cognitive, 
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Several contributory factors need to be considered with regard to 
psychopathology in MG patients. MG is a chronic illness which impacts on an 
individual’s global functioning. Thus neuropsychiatric symptoms may stem 
from a psychological response to the diagnosis of a chronic neurological 
illness, the impact it has on one’s lifestyle and subsequent physical disability 
(Kulaksizoglu, 2007). These symptoms may be further complicated by the 
fluctuating character of MG and the overlap of neurovegetative symptoms 
such as fatigue, decreased energy levels and shortness of breath posing a 
challenge to both the patient and the physician (Juel, 2007). Neuropsychiatric 
symptoms may also be a direct result of the pharmacological treatments used 
in MG. 
 
Although this proposed pilot study will have a small number of participants, we 
aim to assess MG patients with a structured interview, taking cognizance of 
criticism directed at previous work.  We will assess neuropsychiatric 
symptoms using reliable, multi-faceted psychiatric rating scales as well as 
include both patients severity of MG and concomitant medications.  
 
1.3 Thymoma associated Myasthenia Gravis 
 
Thymoma may present with a number of paraneoplastic conditions including 
MG, limbic encephalitis, glomerulonephritis and vitiligo. Thymoma is 
associated with several antibodies which include those against interferon-
alpha, interleukin-12 and muscle antigens, several of which are able to cross 
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variety of neuropsychiatric symptoms including: irritability; depression; 
insomnia; hypersomnia; hallucinations; memory loss and possible progression 
to dementia (Dalmau, 2006).    
 
To our knowledge, there is no data comparing neuropsychiatric symptoms in 
patients with MG and thymoma MG. A case series study by Musha et al 
(1993) reported on three cases of psychosis in thymoma-MG patients. All 
three patients had undergone a thymectomy in the preceding weeks to 
months. The neuropsychiatric symptoms appeared homogenous and 
preceded the onset of MG by several months to years. These symptoms 
worsened or reappeared during relapses of the MG. The underlying 
psychopathology is thought to be due to an autoimmuneparaneoplastic limbic 
encephalitis occurring in patients with thymoma MG.  
 
Our study proposes that neuropsychiatric symptoms are a consequence of 
CNS involvement in MG.  It further attempts to demonstrate that the 
prevalence of neuropsychiatric symptoms is higher in thymoma MG group.  
 
1.4 Motivation for the study  
  
A study undertaken by Williams et al. (2003) revealed that one third of 
patients attending three hospital based general neurology outpatient clinics 
over a six month period, met the criteria for a depressive episode, yet only 
40% of these patients were diagnosed with depression. They found that the 
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patients. A further study undertaken by Stewart et al. (2007) revealed that the 
prevalence of depression in MG was equivalent to that in neuromuscular 
disease, both of which were higher than that in the general population. These 
findings suggest a need for rigorous screening of neurological outpatients for 
psychiatric disorders (Williams, 2003).  
  
The results of research on psychiatric symptoms in MG have been equivocal.  
While it has been reasonably established that psychiatric conditions such as 
anxiety or depression occur more frequently in MG, we are not aware of any 
study which compares psychiatric symptoms and quality of life in MG patients 
with thymoma and those without. The presence of a psychiatric illness may 
also affect the clinical course of the neurological condition by impacting on 
both the patient’s and their family’s quality of life as well as interfering with 
treatment adherence (Kulaksizoglu, 2007).  
 
A clearer understanding of the neuropsychiatric profile in MG may serve to 
guide medication regimens. A number of treatment modalities exist, although 
corticosteroids remain the most widely used agents as immune modulators 
(Juel, 2007). Mania and hypomania as well as depression are well-recognized 
adverse effects of steroid use (Kulaksizoglu, 2007). Brown and Chandler 
(2001) quote a study undertaken by the Boston Collaborative Drug 
Surveillance Program (BCDSP, N=676) which reported that in subjects free of 
psychiatric disease prior to steroid therapy, 1.3% developed severe 
psychiatric disease at low doses of prednisone. The incidence increased to 
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Psychiatric pharmacological treatments e.g. lithium, used in the treatment of 
Bipolar Mood Disorder, may unmask MG or worsen the existing disease 
(Alevizos, 2006).   
 
Referral for psychotherapy may also aid treatment and rehabilitation. A case 
series of four patients with MG who undertook 1-2 years of client-centered 
psychotherapy demonstrated a significant improvement in their myasthenic 
symptoms, reduced fluctuations in their clinical course and required less 
medication compared to controls (Doering, 1993). Thus the treatment of co-
existing psychiatric illness may be important in the management of patients 
with MG.  
 
Should the results of this study reveal that neuropsychiatric symptoms are 
common in MG, clinician awareness will be raised and the motivation for 
rigorous psychiatric screening and improved accessibility to mental health 
services will be supported. 
 
1.5 Implementation Objectives 
 
The results of this research project will be presented to both the Dept. of 
Psychiatry and the Division of Neurology at the University of Cape Town.  
Should the hypothesis prove that the MG population is at risk for psychiatric 
illness in either the MG, thymoma-MG group or both, the following 
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• A larger, controlled study in this area to be undertaken 
• Encourage a collaboration between both departments with regards to 
the management of patients with MG 
• Ensure adequate, simple, screening tools are available to health care 
workers assessing patients with MG 
• Focus on improving the accessibility to the psychiatric services via 
direct referral routes 
• Emphasize the role of the consultant liaison psychiatry team in the 




2.1 Study Design 
 
The pilot study is cross-sectional in design, descriptive in nature with an 
analytic component. The goal of which, is to examine the relationship between 
MG and the incidence of neuropsychiatric symptoms in both MG and 
thymoma-MG. The prevalence of neuropsychiatric symptoms in MG will be 
determined using a battery of psychiatric rating scales. This data will then be 
analyzed to further examine potential causative factors and associated 
variables.  
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The study population consists of all patients able to understand English 
attending the MG clinic at Groote Schuur Hospital (GSH), Cape Town during 
a three month period. This population includes both patients with thymoma-
MG and MG without thymoma. As MG can present at any age, no age limit 
will be applied to the sample population. 
 
Twenty (N=20) randomly selected patients with MG, attending the clinic 
during the period of Dec 2009 to June 2010 with MG, will be assessed. Due to 
the rare nature of thymoma MG (10% of the MG population), a sample of ten 
(N=10) will be randomly drawn from the UCT-MG database (the last 10 
entered into the database representing consecutive clinic attendees). These 
patients will be contacted telephonically and asked to participate. If they 




Upon arrival at the GSH MG clinic, patients will be briefed about the study and 
informed consent taken. Participants will be required to sign a consenting 
document approved by the University of Cape Town Health Science Ethics 
committee. (See appendix). Participants will be handed the Flanagan Quality 
of Life Scale to complete before seeing the neurologist (Flanagan, 1982). 
 
Once the neurological assessment has been completed, the participants will 
be interviewed in a private consultation room in the neurology ward. Dr. 
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thymoma. A number of measurement instruments will be used. Documentary 
sources such as the patient file and assessment sheet will provide basic 
demographic details. These include:  age; gender; address and folder 
number. Data taken from the assessment sheet will include: onset of illness; 
quantified MG score based on that by Tindall (1978); pharmacological 
treatment and non-pharmacological interventions e.g. thymectomy. This data 
sheet will be obtained from the Neurology folder upon completion of the 
psychiatric interview so as not to bias the rater to the condition. 
 
Previous studies have reported limitations with regards to the overlap of 
vegetative symptoms e.g. fatigue, insomnia in both MG and certain psychiatric 
disorders such as depression and have recommended that the focus on 
psychiatric symptoms goes beyond somatic complaints (Kulaksizoglu, 2007).  
We have thus included the BDI-II, which provides an assessment of cognitive, 
somatic, affective and behavioural symptoms associated with depression 
(Beck, 1996). Data from the MG clinic score sheet will be recorded which 
encompasses both reported physical symptoms and objective findings on 
examination. This data will be correlated with the results from the psychiatric 
rating scales. 
 
The neuropsychiatric symptom assessment will include four rating scales 
administered by a mental health professional. These include: The Young 
Mania Rating Scale (YMRS) – a widely used, reliable instrument used in the 
assessment of mania (Altman, 1994); Beck Depression Inventory (BDI-II) – 
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consistent with criteria of the DSM-IV (Beck, 1996); Brief Psychiatric Rating 
Scale (BPRS) – a rapid assessment of global psychiatric symptomatology 
(Overall, 1962); Hamilton Anxiety Rating Scale (HARS) – used to measure 
severity of anxiety symptoms in both clinical and research settings (Hamilton, 
1959). 
 
The interview is estimated to take between 40-45 minutes. 
 
2.4 Pilot studies 
 
The battery of psychiatric rating scales will be piloted on 2 patients attending 
the GSH MG clinic. Logistical and implementation difficulties will then be 
assessed and adjusted accordingly. 
 
3. Data management and analysis 
 
Once the data has been collected in a clinical interview, the data will be 
systematically filed for later processing. The actual scores of each rating scale 
will be calculated and recorded on the completed questionnaire at the time of 
interview. The Quality of Life score sheet will be collected at the start of the 
interview. Copies will be made of the clinical data score sheet acquired by the 
neurology team and filed with the results of the psychiatric interview.  
 
Once the data collection has been completed, it will be processed with the 
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4. Logistics and time schedule 
 
4.1 Responsibilities of investigators/staff 
  
• Both A/Prof. Heckmann and Dr Lewis to advise on both needs and 
discrepancies in the study protocol 
• A/Prof. Heckmann will assist with the simple random sample collection 
of patients with thymoma MG from her existing data base of patients 
• DrHeckmann will contact these patients to arrange a suitable 
appointment time at GSH. Transport costs of these patients will be 
covered if not part of the patients routine assessment 
• A/Prof. Heckmann to alert neurology team of the data collection 
location and periods and direct patients to the waiting area following 
their assessment   
• Dr Freeman to ensure informed consent is taken from each patient 
• Dr Freeman to collect data during the period of 07h00 to 11h30 on 
Friday mornings during the GSH MG clinic 
• Data will be assimilated and pooled by Dr Freeman.  This data will be 
analyzed with assistance from Dr’sHeckmann and Lewis. The 
department may be consulted for additional input from a recommended 
statistician 
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October 2009:  Protocol completion, submission to the 
University of Cape Town Dept. of 
Psychiatry, Dept. of Neurology and Ethics 
Committee. 
 
November 2009: Pilot study rating scales with 2 patients 
attending the GSH MG clinic 
 
December 2009 to June 2010: Data collection and measurement 
 
July 2010: Assimilation of data: checking and 
summarizing 
 
August/Sept 2010: Analyzing and interpreting data 
 




5.1 Available resources 
• Personnel include A/Prof. Jeannine Heckmann (Dept. of Neurology) 
and Dr Ian Lewis (Dept. of Psychiatry) for information, experience and 
guidance. 
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• The University of Cape Town Library to access both textbooks and 
journals. 
• The Internet. 
• R2000.00 Research Grant provided by the Dept. of Psychiatry, UCT.  
Fund managed by Dr John Joska and allocated to M Med Research 
projects that have been approved by the University of Cape Town’s 
Ethics Committee. 
 
5.2 Budget and budget motivation 
• R2000.00 Research grant to assist with transport fees of the patients 
seen outside of their routine clinic follow-up.  The remainder will be 
spent on printing costs, the purchase of a printer and petrol costs. 
 
6. Ethical and legal considerations 
 
The protocol will be submitted to the University of Cape Town Health Science 
Ethics Committee to ensure that the study safeguards patient’s rights and 
welfare. 
 
Each patient participating in the study will be required to give informed 
consent in writing. Each participant must have full capacity to sign consent 
and this consent must be given voluntarily. The consent procedure will include 
disclosure of the purpose of the study as well as the possibility of subsequent 
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Should a participant require further psychiatric intervention or care, a referral 
will be made to either the psychiatric emergency services at Groote Schuur 
Hospital or the Neuropsychiatric outpatient clinic run by Dr Ian Lewis on a 
Thursday morning at Ward C23, Groote Schuur Hospital. 
 
In the event whereby a patient may need to come in for assessment outside 
of the usual clinic time, the patient’s transportation costs e.g. bus or taxi fare, 
will be covered by the research grant of R2000 given to each psychiatric 
registrar who has successfully submitted a research protocol. 
 
7. Reporting of results 
 
A written report will be submitted to the Department of Psychiatry at The 
University of Cape Town as part of the MMed requirements. This will take the 
form of a dissertation.  
 
Results will also be reported back to the scientific community by means of a 
presentation to both the Psychiatry and Neurology Departments at the 
University of Cape Town. Both target groups will play an instrumental role in 
implementing the recommendations formulated from the research findings. 
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NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH 
THYMOMA-ASSOCIATED AND NON-THYMOMA MYASTHENIA 
GRAVIS 
 
i. Objectives of the literature review 
• To acquire up-to-date knowledge pertaining to the intended field 
of study i.e. the presence or absence of neuropsychiatric 
symptoms in myasthenia gravis, studies already undertaken in 
this area and recommendations for future research 
• To identify key terminology used in this field 
•  To identify limitations and difficulties experiencedby researchers 
in previous studies examining this area in order to improve the 
methods and study design of the intended study  
• To identify conflicting viewpoints within this field 
• To assist us in identifyingsuccessful methods used in previous 
studies which could be employed in the intended study allowing 
us to draw comparison 
• To identify needs and gaps of knowledge in the field of 
neuropsychiatry pertaining to myasthenia gravis 
• To identify experts within the field of myasthenia gravis with a 
view to establishing contact for future collaboration  
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The search strategy involved identifying keywords relevant to this study 
and embarking on an online search making use of an established 
database. 
 
The following keywords were used: myasthenia gravis + psychiatric 
symptoms; neuropsychiatry; depression; anxiety; mania; 
hypomania.All reviews, descriptive and controlled studies, published in 
this area, were included. 
 
Pubmed Central is a well-known repository of peer-reviewed research 
reports/articles pertaining to the life-sciences and provided a sound 
database for the online search.(1)As some of the studies in this area 
were performed several decades ago, we did not limit the search to a 
particular time period. Once a number of articles were identified, the 
abstracts were obtained in order to assess the relevance of the article 
to the intended study. Irrelevant studies were excluded and the main 
body/text of the remaining articles were sourced via open access or 
using the University of Cape Town’s ‘easyproxy’ server. 
 
In addition, a hand-search was performed using the bibliographies of 
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Myasthenia Gravis (MG) is a chronic, potentially debilitating, 
autoimmune disease in which pathogenic antibodies are directed at the 
neuromuscular junction (NMJ) of skeletal muscle. The condition can 
present at any age and is characterized by muscle fatigability, which 
may fluctuate during the course of the day and is typically worsened by 
exertion. MG is classified as ocular MG when weakness is limited to 
the eyelids and extraocular muscles or generalized MG when other 
muscle groups are involved e.g. limbs, bulbar or respiratory muscles. 
The majority of MG subjects have detectable pathogenic antibodies to 
the acetylcholine receptor (AChR) directed at the alpha-1 subunit of the 
nicotinic AChR on the skeletal muscle endplate. Approximately 15% of 
these cases are associated with thymoma. MG is the most 
commonparaneoplastic manifestation affecting up to 50% of thymoma 
cases (known as thymoma-MG from this point). Thymoma may worsen 
the prognosis of the MG and symptoms often persist despite 
thymectomy for removal of the tumour (as reviewed in Evoli et al).(2)A 
number of other paraneoplastic syndromes are associated with 
thymoma including neuromyotonia, limbic encephalitis, polymyositis, 
psychosis, hearing loss and sleep disturbance.(3)Limbic encephalitis is 
known to present with a variety of neuropsychiatric symptoms including 
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Psychiatric symptoms in myasthenia gravis 
Occasional reports dating back to the 19th century propose that MG 
also involves central nervous system cholinergic 
neurotransmission.(5,6)This follows observable 
electroencephalographic (EEG) changes in MG patients not accounted 
for by epilepsy or other clinical parameters(7), as well as, altered rapid 
eye movement sleep and abnormal pattern-reversal visually evoked 
potentials in MG patients.(8,9)More recently, several reports have 
demonstrated an increased prevalence of psychiatric disorders in this 
population in an attempt to support this hypothesis. 
 
In the early 1990’s Rohr and colleagues undertook a retrospective 
study in 200 patients with confirmed MG.(10)Up to 20% of this sample 
had been misdiagnosed with a psychiatric disorder at the onset of their 
myasthenic illness. Young women were noted to be most at risk of a 
misdiagnosis. A number of older studies exist supporting an increased 
prevalence of psychiatric disorders within the MG population. 
(11,12)However, these studies have been criticized due to their small 
sample sizes, lack of structured clinical interviews and overlap of 
neurovegetative and physical symptoms associated with MG.(13,14) 
 
More recently, a number of groups, both in the developed and 
developing world have re-examined psychopathology within the MG 
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psychiatric interview (MINI-Plus) and demonstrated high rates of 
depression (26.1%) and anxiety symptoms (46.3%) in their MG 
population (n=41).(15)Their results were similar to those found by Qui 
et al. who, using a larger sample (n=161), found that up to half oftheir 
Chinese MG sample suffered from either depression or dysthymia and 
45.3% had anxiety symptoms.(16)An even larger MG sample (n=251) 
was studied by Suzuki et al.(17)Their group found a depression 
frequency of 13.6% in their study population, pooled from multiple 
sites, and concluded that the dose of oral corticosteroids was a major 
contributing factor.(17)Other groups, such as Paul et al. found that 17% 
of their MG sample were depressed and that this result was 
independent of daily dose of prednisone or disease duration.(18) 
 
Although the above studies report a frequency of depression and 
anxiety that is higher than that of the general population, a number of 
factors should be considered. Firstly, up to one-third of newly referred 
neurology outpatients meet the criteria for a major depressive 
episode.(19)A study undertaken by Stewart et al. demonstrated that 
the frequency of depression in MG was equivalent to that in 
neuromuscular disease.(20)Thus, we cannot infer that the increased 
frequency of psychopathology is unique to MG patient populations. 
Secondly, groups such as Sitek et al. were unable to demonstrate 
neurocognitive deficits in this population once vision and motor function 
were controlled for.(21)They concluded that they were unable to 
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However, they did find an elevated mean Beck Depression Inventory 
(BDI-II) score compared to their control group. Finally, several 
contributory factors should be considered with regards to the 
development of psychopathology in MG patients. Neuropsychiatric 
symptoms may stem from a psychological response to the diagnosis of 
a chronic neurological illness, the impact it has on one’s lifestyle and 
subsequent physical disability.(22)In addition, pharmacological agents 
used in the treatment e.g. corticosteroids may further contribute to the 
development of neuropsychiatric symptoms.(23) 
 
Thymomaand psychiatric symptoms in myasthenia gravis 
Little is known about the nature and frequency of neuropsychiatric 
symptoms in thymoma-MG. A number of antibody-mediated 
paraneoplasticsyndromes  have been associated with thymoma,two of 
which, may present with psychiatric symptoms i.e. limbic encephalitis 
and psychosis. Limbic encephalitis may present with prominent 
neuropsychiatric symptoms including: depression; insomnia; 
hypersomnia; irritability; hallucinations; memory loss and possible 
progression to dementia.(4) 
 
Interestingly, in thymoma-MG the disease frequently persists despite 
thymoma removal requiring further immunosuppressant therapy. 
Musha and colleagues report on three case studies of thymoma-MG, 
all of which demonstrate persistence of neuropsychiatric symptoms 
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(n=151) found that prominent anxiety symptoms correlated with 
thymoma, prednisone dose and severity of MG.(16) Apart from the 
above-mentioned studies and the association with limbic encephalitis, 
most of the larger studies assessing psychiatric manifestation in MG 
cohorts do not comment on the differences between thymoma-MG and 
non-thymoma MG subjects.  
 
iv. Gaps or needs for further research 
Almost all of the studies undertaken in this area highlight the necessity 
for further research. Authors emphasize the need for larger study 
samples with control groups. A detailed quantitative assessment of 
disease severity should be included in all future studies. This includes 
classification into certain subtypes, e.g. thymoma-MG, and an attempt 
to delineate vegetative features of MG vs. depression, e.g. insomnia 
and appetite disturbance. 
 
An important area of research in this field includes the provision of 
evidence-based guidelines on the safety and efficacy of psychotropic 
prescribing in MG factoring in adverse effects, disease progression and 
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Background: Myasthenia gravis (MG) is an acetylcholine receptor antibody-
mediated disease targeting the neuromuscular junction resulting in fatigable 
muscle weakness. A number of reports have suggested a high prevalence of 
psychiatric symptoms amongst MG patients. Approximately 10% of MG 
subjects are found to have an associated thymoma and despite 
thymomectomy, the MG persists. The presence of thymoma may lead to other 
antibody-mediated neuropsychiatric manifestations including limbic 
encephalitis. We hypothesized that the prevalence of neuropsychiatric 
symptoms may be higher in MG subjects with thymoma-associated MG when 
compared with those who have non-thymoma MG. 
 
Aims: This study aims to compare the prevalence of neuropsychiatric 
symptoms in a South African population of non-thymoma MG and thymoma-
associated MG. 
 
Method: A blinded cross-sectional psychiatric evaluation was performed on 
thirty adults with MG. Twenty-one had non-thymoma MG and nine had 
thymoma-associated MG. The severity of MG in each participant was 
assessed by a dedicated MG clinic using the quantified myasthenia gravis 
score (QMGS). The age at symptom diagnosis, years of symptoms before 
and on treatment, timing of thymectomy or thymomectomy and current 
medications were noted.   
 
Neuropsychiatric assessments included: a self-reported 15-item Quality of Life 
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Scale (HAM-A); the Young Mania Rating Scale (YMRS) and the Brief 
Psychiatric Rating Scale (BPRS).  
 
Results: Overall, high rates of moderate to severe depression(33.3%) and 
anxiety(33.3%)symptoms were present across both groups. However, there 
was no significant difference in the frequency and nature of neuropsychiatric 
symptoms between thymoma and non-thymoma MG groups. High scores on 
the BDI-II correlatedpositively with disease severity (p=0.008) as measured by 
the QMGS and presence of respiratory symptoms and tended to occur in 
those with a longer duration of illness (p=0.08). The presence of moderate to 
severe anxiety symptoms was associated with a longer disease duration 
(p=0.035) and showed significant overlap with symptoms of depression 
(p=0.001). There was a tendency towards suicidality (p=0.07) and need for 
psychiatric referral (p=0.08) associated with MG symptoms onset at a 
younger age. 
 
Conclusion: Neuropsychiatric symptoms such as depression and anxiety are 
prevalent in this MG population and necessitate identification and subsequent 
psychiatric referral. No differences could be detected in the prevalence of 
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INTRODUCTION 
 
Myasthenia Gravis (MG) is a chronic, potentially debilitating, autoimmune 
disease in which pathogenic antibodies are directed at the neuromuscular 
junction (NMJ) of skeletal muscle. The condition can present at any age and 
is characterized by muscle fatigability, which may fluctuate during the course 
of the day and is typically worsened by exertion. MG is classified as ocular 
MG when weakness is limited to the eyelids and extraocular muscles or 
generalized MG when other muscle groups are involved e.g. limbs, bulbar or 
respiratory muscles. The majority of MG subjects have detectable pathogenic 
antibodies to the acetylcholine receptor (AChR) on the skeletal muscle 
endplate. 
 
Between 10%-15% of generalized, antibody positive MG cases have an 
associated tumour of the thymus or thymoma, with late-onset patients being 
more commonly affected. MG is the commonest paraneoplastic manifestation 
of thymoma affecting about 50% of patients. A number of additional antibody-
mediated paraneoplastic syndromes have been associated with thymoma 
including neurological disorders such as neuromyotonia, polymyositis, limbic 
encephalitis, psychosis and sleep disturbance as well as autoimmune 
diseases to non-neurological target organs such as haematological and 
skin.(1) Limbic encephalitis frequently presents with neuropsychiatric 
symptoms, which may include depression, irritability, cognitive impairment 
and psychosis.(2) The treatment of thymoma involves surgical removal of the 
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syndromes may persist requiring additional immunosuppressive 
pharmacotherapy. Although psychosis is rare (1) in thymoma, there is a report 
of three cases with persistence of psychotic symptoms despite 
thymomectomy.(3) 
 
In MG, muscle fatigability is mediated largely by the effects of pathogenic 
antibodies directed at the alpha-1 subunit of the nicotinic AChR. Occasional 
reports dating back to the 19th century propose that MG also involves central 
nervous system cholinergic neurotransmission.(4,5)This follows observable 
electroencephalographic (EEG) changes, altered rapid eye movement sleep 
and abnormal pattern-reversal visually evoked potentials in MG patients.(6-8) 
More recently, several reports have demonstrated an increased prevalence of 
psychiatric disorders in this population.(9) Despite these positive findings, 
many MG studies of this nature have been criticized due to their small sample 
sizes, lack of structured clinical interviews and lack of distinction in the overlap 
of neurovegetative symptoms seen in depression and physical symptoms 
associated with MG.(10) In addition, Sitek et al were unable to demonstrate 
neurocognitive deficits in this population once they controlled for vision and 
motor dysfunction.(11) Apart from a small case series (3) and the association 
with limbic encephalitis (1), most of the larger studies assessing psychiatric 
manifestation in MG cohorts do not comment on the differences between 
thymoma-and non-thymoma MG subjects.  
 
Following the observation of psychopathology in thymoma-MG by an 
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more vigilant about an increased frequency of neuropsychiatric symptoms 
amongst thymoma -associated MG compared with non-thymoma MG. To 
answer this we performed a pilot study in which both thymoma and randomly 
selected non-thymoma-MG subjects were blindly assessed using several 
neuropsychiatric questionnaires.  
 
Methods 
The present study is a cross-sectional analysis of 30 MG patients attending a 
dedicated, quaternary, outpatient MG clinic at Groote Schuur Hospital in Cape 
Town, South Africa. Following a routine clinic visit, each participant 
wasinformed of the study and invited to participate. No patient refused to take 
part in the study. Written informed consent was obtained from each study 
participant prior to entry into the study. The University of Cape Town Health 
Sciences Ethics Committee approved the study protocol in compliance with 
the guidelines of The Declaration of Helsinki, sixth revision, 2008. 
 
Study population 
Patientsattending the MG clinic between November 2009 and August 2010 
were invited to take part in our study. All participants had a confirmed 
diagnosis of MG based on fatigable weakness with either a positive anti-
AChR assay (≥0.2nmol/l), a significant clinical response to neostigmine or a 
>10% decremental response on 2 Hz repetitive nerve stimulation.(12) All 
patients attending the clinic followed a standard treatment protocol as 
referenced in Heckmann et al.(13) At the time of diagnosis, patients with 
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intravenous immune globulin) and a thymomectomy was performed at the 
earliest possible time. Non-thymoma, acetylcholine receptor antibody-positive, 
generalized MG ≤45 years, with significant disease are offered a thymectomy 
as standard of care. 
 
Although the hospital generally serves an adult population, we did not limit the 
sample to a particular age-group. During the study period all thymoma-MG 
patients attending the clinic were invited to participate. In addition, prior to 
each clinic the unblinded neurologist randomly identified three to four subjects 
from the booking list to be approached for possible study participation. 
Participants were required to be able to converse in English.Only patients who 
had generalized MG and who were not critically ill e.g. requiring 
hospitalization for decompensating MG, were approached. The interviewer 
(CF) was blinded to presence or absence of thymoma in study participants. 
 
Interviews & tools 
Individuals were interviewed by a psychiatrist (CF) in a private consultation 
room within the clinic. A 16-item self-reported Flanagan Quality of Life Scale 
(QOL) was completed at the beginning of the interview.(14) The 
neuropsychiatric symptom assessment consisted of three validated rating 
scales. These included: the Beck Depression Inventory, second edition (BDI-
II); the Young Mania Rating Scale (YMRS) and the Hamilton Anxiety Rating 
Scale (HAM-A).(15-17) The Brief Psychiatric Rating Scale (BPRS) was 
included to provide a global psychiatric impression of the participant during 
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A brief enquiry was made into previous history of psychiatric diagnosis, past 
or current medical or psychological treatment and history of suicide attempts. 
Participants were referred for further psychiatric assessment and 
management if they expressed current suicidal ideation or scored in the 
moderate to severe range of symptomatology on any of the psychiatric scales. 
Upon completion of the psychiatric interview, each participant’s medical folder 
was retrieved in order to obtain the Quantified Myasthenia Gravis Score 
(QMGS), as used by Heckmann et al.(13)calculated on the day of interview. 
The most recent thyroid stimulating hormone (TSH) level and other pertinent 
data such as comorbid conditions, treatments and dosing were also 
obtained.Age at symptom onset, duration of symptoms prior to diagnosis, 
duration of illness and thymic histology i.e. thymoma or not, were obtained 
from a MG database recorded by the clinic.  
 
Statistical analysis 
Normally distributed data are presented as means and standard deviations 
(SD) whereas ordinal data such as the QMGS score are presented as 
medians and interquartile ranges (IQR). Results from the psychiatric rating 
scales are presented in Table 2 as means, in keeping with broader psychiatric 
literature. Due to the small study sample, non-parametric tests such as the 
Mann-Whitney U Test were used for comparison of longitudinal data between 
two unpaired groups. Fisher’s exact test was used for categorical data on 
www.openEpi.com.(19) The Spearman rank-order correlation coefficient (rs) 
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groups e.g. BDI-II scores and prednisone dose. A significance level of <0.05 




Of the total sample (n=30) included in the study, 21 (70%) participants had 
non-thymoma MG and 9 (30%) had thymoma- MG. The demographic and 
clinical characteristics are included in Table 2. Both groups were 
predominantly female with 16 (76%) females in the non-thymoma MG group 
and 6 (66%) in the thymoma-MG group (p=0.61). At the time of interview, the 
groups were similar in age distribution with an average age of 44.7 years 
(SD±9.8) in the thymoma-MG and 45.0 years (SD±16.9) years in the non-
thymoma group (median for both 46 years; p=0.89). Both groups had a mean 
age of disease onset in their early thirties (non-thymoma MG median onset 
age= 25.0 years; IQR 16.0; 43.0; thymoma-MG median= 39.0; IQR 29.0; 44.0; 
p=0.50).There was no difference in the disease duration prior to the interview 
between the non-thymoma MG group (mean=135.9 months; median 89.0; 
IQR 49.0; 154.0) compared to the thymoma-MG group (mean=65.6 months; 
median=36.0; IQR 13.0; 118.0) (p=0.14). Although the non-thymoma MG 
group was symptomatic for a longer period of time prior to the diagnosis of 
MG being made with an average wait of 11.9 months (SD±25.3; median=6.0) 
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At the time of interview the thymoma-MG group reported predominantly limb 
symptoms (77%) whereas over half the non-thymoma MG group suffered 
from bulbar (52%) and ocular (57%) symptoms; however, the distribution of 
symptoms was not significantly different between the two groups (Table 1; 
p=0.47). The QMGS of disease severity was similar across both groups with a 
median score of 8 (IQR 4.5; 11) in the non-thymoma MG and 10 in the 
thymoma MG group (IQR 4; 11; p=0.76). As expected, higher QMGS scores 
correlated with respiratory symptoms (rs=0.39, p=0.031), higher doses of 
prednisone (rs=0.39, p=0.034) and worse Flanagan QOL scores (rs=-0.51, 
p=0.004).  
 
Six participants (66%) with thymoma-MG and sixteen (76%) with non-
thymoma MG were on corticosteroids. The average daily dose of prednisone 
was similar with 16.3mg/day (SD±16.7) in the non-thymoma- and 17.2mg/day 
(SD±17.2) in the thymoma MG group (p=0.86). Four (19%) with non-
thymoma-MG and two (22%) with thymoma MG were on antidepressant 
therapy (p=0.37). At the time of interview, eight (88%) of the nine subjects 
with thymoma-MG had undergone surgery for thymoma removal and one 
subject wished it to be postponed until after his intended wedding. Ten (47%) 
subjects with non-thymoma MG had undergone a thymectomy for removal of 
their thymus.  
 
When comparing neuropsychiatric symptoms across the thymoma and non-
thymoma groups, no statistical difference was seen in depression, anxiety or 
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sample as a whole, one third of the total sample demonstrated moderate to 
severe symptoms of depression (n=10; 33%) and anxiety (n=10; 33%). 
Moderate to severe depression and anxiety symptoms were associated with 
lower Flanagan QOL scores (rs=-0.69, p=0.0001). At the time of interview 
more severe disease, as measured by the QMGS, was associated with higher 
BDI-II scores (rs=0.47, p=0.008) but not anxiety symptoms (rs=0.08, p=0.69). 
A longer duration of MG disease was associated with both significant anxiety 
(rs=0.38, p=0.035) and depression symptoms (rs=0.37; p=0.045). There was 
no association between duration of symptoms before diagnosis in either of 
these categories (anxiety or depression) suggesting that it was not the 
duration of symptoms pre-treatment but rather duration of disease that 
contributed to depressive state.  
 
Subjects with high BDI scores also had higher scores on the BPRS (rs=0.72, 
p=≤1x10-5) and HAM-A (rs=0.56, p=0.001). They were also more likely to 
have been placed on antidepressant therapy by their medical attendants 
(rs=0.42, p=0.019). Four subjects were identified with moderate to severe 
depression at the time of interview, which had not previously been detected 
by the attending neurological team. Subjects who had been diagnosed with 
depression and placed on antidepressants prior to the study demonstrated 
high scores on the BDI-II (p=0.012). These subjects were also highly 
associated with suicidal behaviour (rs=0.68, p=≤1x10-4) and required 
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In our sample, higher doses of prednisone did not show an association with a 
depressed state (rs=0.28, p=0.14) or prominent anxiety symptoms (rs=-0.08, 
p=0.66). Interestingly, three subjects (10%) in our study met the criteria for 
hypomania and two (6%) were manic at the time of interview, but these 
features were negatively associated with prednisone dose (rs=-0.38; 
p=0.034). The underlying cause or precipitant of the manic/hypomanic 
features remains unknown and four or these subjects required referral for 
further psychiatric evaluation. 
 
As mentioned, current suicidal ideation or previous history of suicide attempt 
was strongly associated with higher scores on the BDI-II (rs= 0.68; p≤1x10-4), 
higher BPRS scores (rs=0.49, p=0.006) and a significant number of these had 
already been diagnosed with depression and were on antidepressants 
(rs=0.58; p=0.006). A younger age of onset revealed a positive trend to 
suicidal behavior (p=0.07) and need for psychiatric referral (p=0.08). Subjects 
who were younger at the time of onset of MG had higher scores on the BPRS 
(rs=-0.47, p=0.007). A number of factors were not associated with suicidal 
behaviour. These include: anxiety symptoms (p=0.25); mania or hypomania 
(p=0.65); QMGS (p=0.18); prednisone dose (p=0.18) and duration of MG 
(p=0.11).Overall, fourteen (46%) of the participants who were interviewed 
required further psychiatric evaluation and management with emphasis on 
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Although we did not find a significant difference in the frequency of 
neuropsychiatric symptoms between thymoma-associated and non-thymoma 
MG, we did reveal prominent psychiatric symptomatology in the group as a 
whole. One third of our total sample were found to be either in a clinically 
depressed state or scored in the moderate to severe range of anxiety 
symptoms on the HAMA-A (Table 2). A third of our subjects reported one or 
more past suicide attempts or exhibited suicidal ideation at the time of 
interview and almost half of the sample required additional psychiatric 
evaluation and management, particularly those with younger age of onset. 
Although 19-20% of our sample had been treated with antidepressants by the 
attending neurologists, they remained symptomatic for depression and/or 
anxiety and required further psychiatric review.  
 
The high prevalence of psychiatric symptoms in MG, particularly depressive 
and anxiety disorders, is well described. Our results corresponded with a 
South American group who evaluated a similar sample size, using a 
structured psychiatric interview (MINI-Plus), and diagnosed 26% of their 
sample with a depressive disorder and 46% with an anxiety disorder.(20) We 
used the BDI-II as a measure of a depressed state and found higher overall 
scores compared to two larger groups, North American (11) and Japanese 
(21) who used the same assessment tool. Although the Japanese cohort was 
older, their myasthenia was less severe based on the MG Foundation of 
America (MGFA) quantitative MG score compared with our cohort whereas 
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Our findings revealed a number of factors associated with a depressed state 
in MG. These included: more severe disease with or without the presence of 
respiratory symptoms; co-morbid anxiety symptoms; suicidality and 
concurrent antidepressant therapy. The Japanese group found an association 
with corticosteroid dose and depression, but their doses appeared far lower 
than our patients' current dose(21) We, and others (22) could not demonstrate 
an association between prednisone dose and severity of depression. Although 
our results stated otherwise, treatment with corticosteroids is a well-known 
precipitant of psychiatric disturbance, particularly affective disorders, and 
should be considered in the aetiology of psychopathology in MG.(22) 
 
Six (20%) of our subjects reported that they were on antidepressant therapy 
at the time of interview, five of whom required psychiatric referral due to 
inadequate control of symptoms. These five subjects all scored in the 
moderate to severe range of depression symptoms on the BDI-II despite 
antidepressant therapy. Although depression had been identified and 
antidepressant therapy commenced in several subjects with severe 
depression prior to our assessment, a proportion of participants, not 
previously diagnosed, were found to be depressed at the time of interview. 
MG subjects with high scores on the BDI-II were also at significantly 
increased risk for suicidality, as defined by one or more previous suicide 
attempts, or current suicidal ideation. Suicidal behaviour is not widely reported 
in MG literature and highlights the importance of a psychiatric assessment in 
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One-third of our sample reported moderate to severe anxiety symptoms at the 
time of interview which is lower than the 46% seen in a large Chinese cohort 
using the same anxiety rating scale (HAM-A).(23) In contrast to our findings, 
their high frequency of anxiety correlated with both the presence of thymoma 
and prednisone dose. Some reports have suggested that anxiety symptoms 
such as dyspnoea are more prevalent in MG patients with bulbar and 
respiratory symptoms, as reviewed in Kulaksizoglu.(10) Despite the 
association of respiratory symptoms with depression, we could not find an 
association with anxiety symptoms in our cohort. 
 
Five subjects with manic/hypomanic features were identified in our sample 
(16%) and to our knowledge, this has not been previously reported in MG. 
The reliability of the YMRS is limited as this scale reflects the clinical picture 
over a short period and not over the several days needed to make the 
diagnosis of mania or hypomania. Mania and hypomania are often thought to 
arise as a consequence of corticosteroid therapy, but in our sample the 
presence of these features did not correlate with prednisone dose. 
Furthermore, we could not find an association with antidepressant therapy as 
only one of these five individuals was on antidepressants at the time of 
interview, and only two subjects (both hypomanic) had thymoma. In order to 
judge its relevance, this finding would need to be examined in greater depth 
using a large sample and rigorous assessment of all aspects of mood. 
 
Neuropsychiatric symptoms may arise from factors other than the myasthenic 
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diagnosis of a chronic neurological illness, the impact that the illness has on 
one’s lifestyle and subsequent physical disability.(24) Although the frequency 
of depression in our study is higher than the lifetime prevalence of the South 
African population (9.7%) (25), it is similar to that seen in a general neurology 
outpatient population (33%).(26) Thus, we cannot infer from our results that 
MG underlies the pathogenesis of psychopathology in MG subjects.(27) 
 
This study has several limitations. Our study sample was small as this was a 
pilot study to assess the viability of a larger study examining the MG patient 
population attending a clinic in a tertiary level hospital. The study was 
undertaken over a relatively short period and patients with active/unstable 
disease or more symptoms are more likely to have more frequent follow-up 
visits introducing a selection bias.Due to limited resources, a battery of 
validated psychiatric rating scales were used in the interview to assess 
depressive, anxiety and manic symptoms based on those used in similar MG 
studies. A detailed psychiatric assessment examining broader 
psychopathology e.g. cognitive impairment, personality disorders and 
substance abuse was not undertaken and the authors recommend the 
inclusion of these aspects in future MG studies of this nature. A further 
limitation pertains to the BDI-II, which is a subjective measure of the cognitive 
and neurovegetative aspects of depression. However our findings, using brief 
rating scales, reflect similar results to that seen in the few studies that have 
employed structured psychiatric interviews, which are often time-consuming 
and require specialized training. As part of our QOL assessment we enquired 
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assessing daily function in MG. We did not assess socioeconomic status, 
which could impact on psychopathology, and this quaternary referral MG clinic 
may represent a biased patient population due to the selective referral of 
more severe cases. 
 
Conclusion 
We found a high frequency of psychiatric disorders, particularly depression 
and anxiety, in this South African population with myasthenia gravis. Our 
results highlight the need for systematic depression screening within the 
outpatient clinic in order to detect all depressed patients as well as to monitor 
ongoing symptoms. Particular attention should focus on subjects with severe 
MG and those with a long duration of illness. Simple screening tools, such as 
the BDI-II and HAM-A, are widely accessible and will detect subjects with both 
depression and anxiety as well as those who are experiencing suicidal 
ideation. Once identified, these subjects should be assessed for 
pharmacotherapy and possible referral to psychiatric services. 
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Table 1. Psychiatric rating scales and measurements 
 
Scale Measure Cut off values 
1. BDI-II Depression 0–13: minimal depression;  
14–19: mild depression;  
20–28: moderate depression;  
29–63: severe depression 
2. HAM-A Anxiety symptoms 14-17: mild anxiety  
18-24: moderate anxiety 
 25-30: severe anxiety 
3. YMRS Mania/hypomania 8-12: hypomania 
13-60: mania 
4. BPRS Measures multiple domains in psychopathology and 
is used to assess change in severity over time. 
0-31: mildly ill 
32-41: moderately ill 
42-53: markedly ill 
BDI-II, Beck Depression Inventory; HAM-A, Hamilton Anxiety Rating Scale; YMRS, Young 
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Table 2. Clinical and demographic characteristics of 30 myasthenia gravis (MG) patients 
attending the Myasthenia Gravis Clinic of Groote Schuur Hospital, South Africa. 





Male/female 5/16 3/6 0.61 
Age, mean (±SD), years** 45.0 (16.9) 44.7 (9.8) 0.89 


































Duration of symptoms prior to 
diagnosis, mean (±SD), months 
11.9 (25.3) 6.3 (7.5) 0.39 





























Antidepressant Therapy n, (%)  4 (19%) 2 (22%) 0.37 
Thymectomy/Thymomectomy n=10 (52%) n=8 (88%) 0.043 
 
Legend: *refers to duration prior to interview 
 **On day of interview 
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Table 3.  Neuropsychiatric symptoms in thymoma-associated MG vs. non-thymoma MG 












BPRS score, mean (SD) 12.2 (6.5) 13.1 (6.8) 10.3 (5.9) 0.30 
BDI-II score, mean (SD) 16.3 (9.1) 17.8 (9.8) 12.8 (6.2) 0.16 
HAM-A score, mean (SD) 13.7 (8.8) 14.2 (9.1) 12.7 (8.7) 0.67 
YMRS score, mean (SD) 4.0 (4.3) 3.9 (4.4) 4.2 (4.0) 0.87 
Suicidality n, (%) 9 (30) 7 (33) 2 (22) 0.65 
Psychiatric referral n, (%) 14 (46) 11 (52) 3 (33) 0.42 
 
BPRS, Brief Psychiatric Rating Scale; BDI-II, Beck Depression Inventory; HAM-A, Hamilton 
Anxiety Rating Scale; YMRS, Young Mania Rating Scale 
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Part D: Appendices 









0 .... ..,mII 
T<lt~Pill_UJl ' _,1211*'''' 
_ '0 sf ..... 
NOJlIICT TrI'lJI: Na/aOPS'fOOATlUC'ncJ'I'OM9 U<I PATlBNTS WITH TlII'MOMA 
AHOHOH-nn'MONA M'(AmtiMA CIlAV15 
ltio.,........,_,... ........ _," ___ Iou ....... -"' .. _...tr. 
__ .. _ ...... _iI' ... __ ~ ... ., __ ...... _ 
_ "' ..... 1( .... -..... ............. ___ ,...,.. .. ""'--....... 110. 
__ 0li0< .......... _ -. of .. .....,. _ ... "'~_'"' •• ~_ 
IN S 
__ ... IlECU7Io .. ,.- , 
pp ,';;;' ,'~_"-_I"II'MI,lOOl6l1_ 











	   65	  






FACULTY OF HEALTH SCIENCES 
H ~n IItsc.rdI BJlles COI'M\~ 
Depanment of Psyc: II iatry and Mental Health. 12. Groote ScbulJ1' Ho pital, 
Approval requested 10f' additional year for study titled: 
NEUROPSYCHIATRIC SYMPTOMS IN PATtEHTS WITH THYMOMA AND NON· 
THYMOMA MYASTHENIA GRAVIS 
Protocol ,..maJn. unchanged .nd additional time I. requlrecj to complete the data 
analy.la end write-up. 
I RESEARCH ETliICS COMMmee 
14 OCT 20m 
I HEAlTn SClENCES FACUL1Y 
~~~.RSm O!~~· 
15·to ·tO 



















NIVERSITY OF CAPE TOWN 
12 June 2009 
Prof. M. Blockman 
Chairperson, HSF Human Ethics Committee 
Room E52-24, GSH 
OMB 
Department of Medicine 
Division of Neurology 
JD Heckmann FCP (SAl Neurology PhD (UCn 
ASSOCIATE PROFESSOR JD HECKMANN 
EB . 74 Groote Schuur Hospital 
Observatory· 7925 . Cope Town· South Africa 
Telephone : +27 214043263 
Fox: +27 214066251 
Email: ieanine.heckmann@uct.ac.za 
PROJECT TITLE: NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH 
THYMOMA AND NON-THYMOMA MYASTHENIA GRAVIS 
Dear Prof. Blockman 
This letter serves to indicate my support for the application of Dr Carla Freeman from the 
Department of Psychiatry, to perform a study in the Division of Neurology towards a 
MMed. Dr Freeman hopes to recruit about 30 patients for neuropsychiatric evaluations 
from the Myasthenia Gravis clinic at UCT/GSH, during their regular clinic visits. I have 




PROF. J. HECKMANN 
SPECIALIST NEUROLOGIST 
DIVISION OF NEUROLOGY 
WARD E7/E8 GROOTE SCHUUR HOSPITALlUCT 
hlr .J d r nl 'Y 










	   67	  
Appendix D Informed Consent Form (ICF) 
	  
Consent	  and	  information	  pamphlet	  
	  
NEUROPSYCHIATRIC	  SYMPTOMS	  IN	  THYMOMA	  AND	  NON-­‐THYMOMA	  
MYASTHENIA	  GRAVIS	  
	  
Dr	  CP	  Freeman	  (Dept.	  of	  Psychiatry,	  UCT),	  A/Prof	  J	  Heckmann	  (Neurology,	  




We	  would	  like	  to	  invite	  you	  to	  participate	  in	  a	  research	  study,	  the	  aim	  of	  which	  is	  
to	  answer	  the	  following	  question:	  
	  
Myasthenia	  Gravis	  (MG)	  is	  often,	  although	  not	  always,	  a	  chronic,	  debilitating	  
autoimmune	  disease	  characterized	  by	  muscle	  weakness	  which	  may	  fluctuate	  
during	  the	  course	  of	  the	  day	  and	  is	  worsened	  by	  exertion.	  	  Some	  patients	  suffer	  
from	  psychiatric	  problems	  such	  as	  depression	  and	  anxiety	  at	  the	  same	  time	  as	  their	  
MG	  symptoms.	  	  Also,	  some	  patients	  develop	  a	  thymoma,	  which	  may	  sometimes	  be	  
associated	  with	  psychiatric	  symptoms.	  	  Our	  study	  aims	  to	  determine	  how	  often	  
these	  symptoms	  occur	  in	  MG	  and	  whether	  these	  symptoms	  differ	  in	  patients	  with	  or	  
without	  thymoma.	  	  This	  will	  be	  important	  in	  deciding	  who	  needs	  psychiatric	  
evaluation	  and	  to	  improve	  the	  treatment	  offered	  to	  our	  patients.	  
	  
Myasthenia	  Gravis	  is	  a	  disease	  that	  can	  affect	  an	  individual	  at	  any	  age.	  	  Many	  
people	  with	  myasthenia	  gravis	  report	  great	  difficulty	  adjusting	  to	  the	  impact	  that	  
the	  disease	  has	  on	  their	  day	  to	  day	  lives.	  	  They	  may	  even	  experience	  mild	  to	  
severe	  psychiatric	  symptoms	  such	  as	  low	  mood,	  anxiety,	  insomnia	  and	  feelings	  of	  
hopelessness.	  	  	  	  Our	  study	  intends	  to	  determine	  how	  many	  people	  with	  
myasthenia	  gravis	  suffer	  from	  psychiatric	  symptoms	  and	  whether	  the	  actual	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If	  you	  agree	  to	  participate	  in	  the	  study,	  you	  will	  be	  asked	  to	  sign	  this	  consent	  
form,	  giving	  permission	  for	  us	  to	  include	  your	  information	  in	  the	  study.	  	  You	  will	  
be	  interviewed	  by	  a	  mental	  health	  professional	  in	  a	  private	  room	  on	  the	  same	  
morning	  as	  the	  Myasthenia	  Clinic	  at	  Groote	  Schuur.	  	  The	  interview	  will	  take	  35-­‐
40	  minutes.	  	  Your	  routine	  clinic	  visit	  will	  go	  ahead	  as	  planned.	  	  Should	  we	  find	  
during	  the	  course	  of	  the	  interview	  that	  you	  are	  suffering	  from	  a	  psychiatric	  
illness	  and	  in	  need	  of	  further	  help,	  we	  will	  refer	  you	  to	  your	  local	  psychiatric	  
service	  with	  a	  comprehensive	  letter	  requesting	  a	  full	  assessment.	  
	  
The	  information	  gathered	  in	  the	  interview	  will	  remain	  confidential.	  	  This	  
research	  project	  has	  been	  formally	  approved	  by	  the	  University	  of	  Cape	  Town	  
Health	  Science	  Ethics	  Committee.	  	  Please	  contact	  their	  offices	  at	  (021)	  406-­‐6338	  




(Name	  of	  participant	  in	  block	  letters)	  
	  
have	  read	  and	  understand	  all	  of	  the	  information	  given	  to	  me	  about	  my	  
participation	  in	  this	  study.	  	  I	  have	  been	  given	  the	  opportunity	  to	  discuss	  it	  and	  
ask	  questions.	  	  I	  voluntarily	  agree	  to	  take	  part	  in	  the	  study	  and	  have	  received	  an	  
information	  sheet	  outlining	  the	  details	  of	  the	  study.	  	  I	  understand	  that	  I	  am	  able	  
to	  withdraw	  from	  this	  study	  at	  any	  time	  knowing	  that	  this	  will	  not	  affect	  the	  
quality	  of	  my	  subsequent	  clinical	  management	  or	  care.	  
	  
Participant	  signature:	  _________________________	  Date:	  __________________	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Appendix EData collection sheet 
 
DATA	  COLLECTION	  SHEET	   	   	   	   	   DATE:___________	  
NEUROPSYCHIATRIC	  SYMPTOMS	  IN	  PATIENTS	  WITH	  THYMOMA-­‐
ASSOCIATED	  AND	  NON-­‐THYMOMA	  MYASTHENIA	  GRAVIS	  
	  
Dr	  Carla	  Patricia	  Freeman,	  Email:	  freecarla@gmail.com	  







1.	   Date	  of	  onset	  of	  MG	  symptoms:	  	  	  
	  
Year	   Month	  	   Day	   duration	  
2.	   Date	  of	  MG	  diagnosis:	  	  
	  
Year	   Month	   Day	   duration	  
3.	   Antibody	  level	  at	  diagnosis:	  
	  
	   	  
4.	   Initial	  diagnosis	  at	  onset	  of	  
symptoms:	  
	  
	   	  
5.	   MESTINON	  
	  
YES	  -­‐	  1	   NO	  –	  0	   	  
Current	  dose:	   	   	  
6.	   PREDNISONE	  
Current	  dose:	  
Daily	  dose:	  
Alternate	  daily	  dose:	  
Duration	  current	  dose:	  months	  
Duration	  of	  prednisone:	  years	  
Steroid	  sparing	  agent:	  (name)	  
Duration	  of	  steroid	  sparing	  
agent:	  
	   	   	  
YES	  -­‐	  1	   NO	  –	  0	   	  
YES	  -­‐	  1	   NO	  –	  0	   	  
	   	  
	   	  
	   	  
	   	  
7.	  
	  






	   	   	  
YES	  –	  1	   NO	  –	  0	   	  
YES	  –	  1	   NO	  –	  0	   	  
YES	  –	  1	   NO	  –	  0	   	  
YES	  -­‐	  1	   NO	  –	  0	   	  
8.	   Flanagan	  Quality	  of	  life:	  score	  
	  
	   	  
9.	   Beck’s	  Depression	  Inventory:	  
score	  
	  
	   	   	  
10.	   Brief	  Psychiatric	  Rating	  Scale:	  
score	  





















Hamilton	  Anxiety	  Rating	  Scale:	  
score	  
	   	  
12.	   Young	  Mania	  rating	  scale:	  score	  
	  
	   	  






	   	  
	  







	   	  
	  
Previous	  suicide	  attempt:	   YES	  -­‐	  1	   NO	  -­‐	  0	  
Seeing	  psychiatrist/psychologist	  
at	  present:	  
YES	  -­‐	  1	   NO	  -­‐	  0	  





	   	  
Month:	  
	  
Year:	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QUALITY OF LIFE SCALE (QOL)
Please read each item and circle the number that best describes how satisfied you are at this time. Please
answer each item even if you do not currently participate in an activity or have a relationship. You can be
satisfied or dissatisfied with not doing the activity or having the relationship.
Mostly Mostly
DelightedPleased Satisfied Mixed DissatisfiedUnhappy Terrible
1. Material comforts home, food, conveniences,
financial security . . . . . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
2. Health - being physically fit and vigorous  . . . 7 6 5 4 3 2 1
3. Relationships with parents, siblings & other 
relatives- communicating, visiting, helping  . . . 7 6 5 4 3 2 1
4. Having and rearing children . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
5. Close relationships with spouse or 
significant other . . . . . . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
6. Close friends  . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
7. Helping and encouraging others, 
volunteering, giving advice . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
8. Participating in organizations and 
public affairs  . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
9. Learning- attending school, improving 
understanding, getting additional knowledge . . 7 6 5 4 3 2 1
10. Understanding yourself - knowing your assets 
and limitations - knowing what life is about . . 7 6 5 4 3 2 1
11. Work - job or in home . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
12. Expressing yourself creatively  . . . . . . . . . . . . 7 6 5 4 3 2 1
13. Socializing - meeting other people, 
doing things, parties, etc  . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
14. Reading, listening to music, or observing 
entertainment . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 5 4 3 2 1
15. Participating in active recreation . . . . . . . . . . . 7 6 5 4 3 2 1
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Beck Depression I 
Inventory 
CRTN: __ CRF number: ___ Page 14 V04n 
Baseline 
patient inits: ____ _ 
Name: __________________ Marital Status: ____ Age: ___ Sex: __ _ 
Occupation: ________________ Education: 
Instructions: This questionnaire consists of 21 groups of statements. Please read each group of statements carefully, and 
then pick out the one statement in each group that best describes the way you have been feeling during the past two 
weeks, including today. Circle the number beside the statement you have picked. If several statements in the group 
seem to apply equally well, circle the highest number for that group. Be sure that you do not choose more than one 
statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 (Changes in Appetite). 
1. Sadness 
o I do not feel sad. 
I feel sad much of the time. 
I am sad all the time. 
I am so sad or unhappy that I can't stand it. 
2. Pessimism 
o I am not discouraged about my future. 
I feel more discouraged about my future than I 
used to be. 
I do not expect things to work out for me. 
I feel my future is hopeless and will only get 
worse. 
3. Past Failure 
o I do not feel like a failure. 
I have failed more than I should have. 
As I look back, I see a lot of failures. 
I feel I am a total failure as a person. 
4. Loss of Pleasure 
o I get as much pleasure as I ever did from the 
things I enjoy. 
I don't enjoy things as much as I used to. 
I get very little pleasure from the things I used 
to enjoy. 
I can't get any pleasure from the things I used 
to enjoy. 
5. Guilty Feelings 
I don't feel particularly guilty. 
I feel guilty over many things I have done or 
should have done. 
I feel quite gUilty most of the time. 
I feel guilty all of the time. 
6. Punishment Feelings 
I don't feel I am being punished. 
I feel I may be punished. 
I expect to be punished. 
I feel I am being punished. 
7. Self-Dislike 
I feel the same about myself as ever. 
I have lost confidence in myself. 
I am disappointed in myself. 
I dislike myself. 
8. Self-Criticalness 
o I don't criticize or blame myself more than usual. 
I am more critical of myself than I used to be. 
I criticize myself for all of my faults. 
I blame myself for everything bad that happens. 
9. Suicidal Thoughts or Wishes 
o I don't have any thoughts of killing myself. 
I have thoughts of killing myself, but I would 
not carry them out. 
I would like to kill myself. 
I would kill myself if I had the chance. 
10. Crying 
I don't cry anymore than I used to. 
I cry more than I used to. 
I cry over every little thing. 
I feel like crying, but I can't. 
tID\ THE PSYCHOLOGICAL CORPORATION" Page 1 
W Harcourt Brace & Company 
-Or-Ian-do-.-ao.-ton-'-New-)br~~~ -Fra..::..OC1-·ICO....:;.-A-d .. - .. -. DaI-w COpyrlgnt COl 1996 by Aaron T. Beck 




























Young Mania Rating Scale 
(clinician administered) 
Rater: 
Patient's personal, details 
Date: 
Name: Age: ........ ..... Gender: M/F 
Guide for scoring items: 
The· pUrpose of ~acti . item. isto rate the severity of that aQnormatity j·n the pa~ent. ~en 
several keys are given for a particular grade of severity. the presence of only one· is 
required to qualify for that rating . 
The keys provided are guides. One can ignore the keys if that Is necessary to indicate 
severity. althOugh this should be the exception ratherthan the rule: 
Scoring between the points given (whole or half pointsf is possible and encouraged after 
experience with the scale Is: acquired. This is particularty useful· when severity of a 
particular nom in a patient does not follow the progression indicated by the keys. 
1. Elevated mood 
Absent 
Mildly or possibly increased on questioning 
Definite subjective elevation, optimistic, self-confident, cheerful, appropriate 
to content 
Elevated, inappropriate to content, humorous 
Euphoric, inappropriate laughter, singing 
2. Increased motor activity energy 
Absent 
Subjectively increased 
Animated. gestures increased 
Excessive energy, hyperactive at times, restless (can be calmed) 
Motor excitement, continuous hyperactivity (cannot be calmed) 
3. Sexual interest 
Normal, not increased 
Mildly or posSibly increased 
Definite subjective increase on questioning 
Spontaneous sexual content, elaborates on sexual matters, 
hypersexual by self-report 
Overt sexual acts (towards patients, staff or interviewer) 
© Young RC, Biggs rr, Ziegler VT et nl. A rating scale for mania: reliability, validity and sensitivity. 















Reports no decrease in sleep 
Sleeping less than normal amount by up to 1 hour 
Sleeping less than normal by more than 1 hour 
Reports decreased need for sleep 




Irritable at times during the interview, recent episodes of anger or annoyance 
on ward 
Frequently irritable during interview, short and curt throughout 
H.ostile, uncooperative, interview impossible 
6. Speech (rate and amount) 
No increase 
Feels talkative 
Increased rate or amount at times, verbose at times 
Push, consistently increased rate and amount, dlfficurt to interrupt 
Pressured, uninterruptible. continuous speech 
7. Language-thought disorder 
Absent 
Circumstantial. mild distractibility, quiet thoughts 
Distractible, loses goal of thoughts, changes topic frequently, racing thoughts 
Flight of ideas, tangentiality, difficult to follow, rhyming, echolalia 
Incoherent. communication impossible 
8. Content 
Normal 
Questionable plans, new interests 
Special project(s). hyperreliglous 
Grandiose or paranoid ideas, ideas of reference 
Delusions, hallucinations 
© Young RC, Biggs rr, Ziegler VT et al . A rating scale for mania: reliability, validity and sensitivity. 










































































9. Disruptive-aggressive behaviour 
Absent, cooperative 
Sarcastic, loud at times, guarded 
Demanding, threats on ward 
Threatens interviewer, shouting, interview difficult 
Assaultative, destructive, interview impossible 
10. Appearance 
Appropriate dress and grooming 
Minimally unkempt 
Poorly groomed, moderately dishevelled, overdressed 
Dishevelled, partly clothed, garish make-up 
Completely unkempt, decorated, bizarre garments 
11 . Insight 
Present, admits illness, agrees with need for treatment 
Possibly ill 
Admits behaviour change, but denies illness 
Admits possible changes in behaviour, but denies illness 
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Please enter the score for the term which best describes the patient's condition 0 = not assessed, 1 = 
not present, 2 = very mild, 3 = mild, 4 = moderate,S = moderately severe, 6 = severe, 7 = 
extremely severe 
r-l_._S_- 0_M~A_-~C_~_--_N_~_;_~_-_--_-~~=_- _ _ -_ -_ -_ -_ -_ -_ --------,-- ---------:-- -~l 
Degree of concern over present bodily health. Rate the degree to 
which physical health Is perceived as a problem by the patient, 
whether compla ints have a realistic basis or not. 
o 0 o 1 o 2 o 3 o 4 
o 5 o 6 
o 7 
L-__________________________ ____ -L _ _ ___ _ _ _____ _ ~ 
2.ANXETY 
1------------------ -.,--- ----
Worry, fear, or over-concern for present or future. Rate solely on 
the basis ot verbal report of patient's own subjective experiences_ 
Do not Infer anxiety from physical signs or from neurotic defense 
mechanisms. 
o 0 o 1 
B ~ o 4 o 5 o 6 o 7 
L-_________ _ ____________ -'-_________________ ~ 
---· --1 - ------ - - -------- - ----------
3. EMOTIONAL WITHDRAWAL 
I--------------------------------~-----------------~ 
Deficiency In relating to the Interviewer and to the Interviewer 
situation. Rate only the degree to which the patient gives the 
Impression of tailing to be In emotional contact with other people 
In the Interview situation. 
o 0 o 1 
I B ~ 
i B ~ 
! 0 6 10 7 
-' 
---- ------ ----- -- ------- - --- -- - - --------- - -------, 
4. CONCEPTUAL DISORGANIZATION 
Degree to which the thought processes are confused, 
disconnected, or disorganized. Rate on the basis of Integration of 
the verbal products of the patient; do not rate on the basis of 
patient's subjective impression of his own level of functioning 
www.cnsforum.com 



















- --- ----- - ----
S.GUILT FEELINGS 
Over-concern or remorse for past behavior. Rate on the basis of 0 0 
the patient's subjective experiences of guilt as evidenced by 0 1 





--------.--'-- ----- -----"--~--- -~.------- --
6. TENSION 
Physical and motor manifestations of tension "nervousness', and 0 0 
heightened activation level. Tension should be rated solely on the 0 1 
basis of physical signs and motor behavior and not on the basis of 0 2 





r-'--'--_ --- ----- ---- ---------- ---.-- -.- l 
17; MANNERISMS AND POSTURING 
~ 
Unusual and unnatural motor behavior, the type of motor 0 0 I behavior which causes certain mental patients to stand out in a 0 1 crowd of normal people. Rate only abnormality of movements; do 0 2 





._".<~ __ _ ~ _ __ ~,~, __ ·_ .~~·_· __ .~c 
re. GRANDIOSITY -~---l i 
--1 
Exaggerated self-opinion, conviction of unusual ability or powers. 0 
! 
0 I Rate only on the basis of patient's statements about himself or 0 1 self-In-relatlon-to-others, not on the basis of his demeanor In the 0 2 






















9. DEPRESSIVE MOOD 
Despondency in mood. sadness. Rate only degree of 
despondency; do not rate on the basis 0 inferences concerning 
depression based upon general retardation and somatic 
complaints. 
o 0 o 1 
8 ~ o 4 
o 5 
8~ 
r - --- --- -:--- -·--·------·- --·- ··- - ·- -···-·--·- -
l 10. HOSTILITY 
i 
1------------------ .----,- ----- - - -- ----
Animosity, contempt, belligerence, disdain for other people 
outside the Interview situation. Pate solely on the basis of the 
verbal report of feelings and actions of the patient toward others; 
do not Infer hostility from neurotic defenses, anxiety, nor somatic 
complaints. (Rate attitude toward Interviewer under 
uncooporatlveness").O 




1 06 rD 7 
~-
11. SUSPICIOUSNESS 
-._- ----- -. ·- -----~-·----l 
--------- --- - --- -,--.. _._- - _._._----_. 
Belief (delusional or otherwise) that others have now, w have had 
In the past, malicious or discriminatory intent toward the patient. 
On the basis of verbal report, rate only those suspicions which are 
currently held whether they concern past or present 
clrcumstanes. 
o 0 o 1 
8 ~ o 4 
o 5 o 6 o 7 
! ---- -_._- ---_._ - _. __ ._- -
! 1;2. HALLUCINATORY BEHAVIOR 
I 
Perceptions without normal external stimulus correspondence. I· 0 0 
Rate only those experiences which are reported to have occurred " 0 1 
within the last week and which are described as distinctly different 0 2 





















r·---·-----,---~'-"---· ---:-:-·~-·- · · --:-:-:- '''-- ''J 
~1_3_._M_O_T_OR __ R_ET __ A_R_D_A_T1 __ 0_N ________________________ ~ ______________ .~ .. ~~ ___ -~ 
Reduction in energy level evidenced in slowed movements. Rate 0 0 .' I 
on the basis of observed behavior of the patient only; do not rate 0 1 ! 
on the basis of patient's subjective impression of own energy 0 2 
level. 0 3 
r'-'- -"-'--~--'--"-'--'- '-" '-----
114.UNCOOPERATIVENESS 
Evidence d resistance, unfriendliness, resentment and lack of 
readiness to cooperate with the Interviewer. Rate only on the 
basis of the patients attitude and responses to the interviewer and 
the interview situation; do not rate on basis of reported 
resentment or uncooperativeness outside the Interview situation. 
r'-"-- ~~'---------'''--' ~--"- '~":'-'--'-'--':"-'-.-
15. UNUSUAL THOUGHT CONTENT 
o 4 
o 5 
D 6 o 7 
o 0 o 1 
B ~




Unusual, odd, strange or bizarre thought content. Rate here the 
degree of unusualness, not the degree of disorganizations of 
thought processes. 
~~;;;~~~;;;-~---.- .,....... ,,-:--.... -. _._...,.._--------
la ~ 
10 2 
i 0 3 
10 4 
! 0 5 
! 0 6 
' 0 7 
I 
f
-Reduced emotional tone, apparent lack of normal feeling O~I. -0- -0---'---- ._" .... _-_.-
involvement , 0 1 
102 
! 0 3 ' 























- -- - , --_._---------
18. DISORIENTATION 
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Below is a list of phrases that describe certain feeling that people have. Rate the patients by finding the answer which best describes the extent
to which he/she has these conditions. Select one of the five responses for each of the fourteen questions.
0 = Not present, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very severe.
Hamilton Anxiety Rating Scale (HAM-A)
! ! ! ! ! ! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
1 Anxious mood 0 1 2 3 4
Worries, anticipation of the worst, fearful anticipation, irritability.
2 Tension 0 1 2 3 4
Feelings of tension, fatigability, startle response, moved to tears
easily, trembling, feelings of restlessness, inability to relax.
3 Fears 0 1 2 3 4
Of dark, of strangers, of being left alone, of animals, of traffic, of
crowds.
4 Insomnia 0 1 2 3 4
Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue
on waking, dreams, nightmares, night terrors.
5 Intellectual 0 1 2 3 4
Difficulty in concentration, poor memory.
6 Depressed mood 0 1 2 3 4
Loss of interest, lack of pleasure in hobbies, depression, early waking,
diurnal swing.
7 Somatic (muscular) 0 1 2 3 4
Pains and aches, twitching, stiffness, myoclonic jerks, grinding of
teeth, unsteady voice, increased muscular tone.
8 Somatic (sensory) 0 1 2 3 4
Tinnitus, blurring of vision, hot and cold flushes, feelings of weakness,
pricking sensation.
9 Cardiovascular symptoms 0 1 2 3 4
Tachycardia, palpitations, pain in chest, throbbing of vessels, fainting
feelings, missing beat.
10 Respiratory symptoms 0 1 2 3 4
Pressure or constriction in chest, choking feelings, sighing, dyspnea.
11 Gastrointestinal symptoms 0 1 2 3 4
Difficulty in swallowing, wind abdominal pain, burning sensations,
abdominal fullness, nausea, vomiting, borborygmi, looseness of
bowels, loss of weight, constipation.
12 Genitourinary symptoms 0 1 2 3 4
Frequency of micturition, urgency of micturition, amenorrhea,
menorrhagia, development of frigidity, premature ejaculation, loss of
libido, impotence.
13 Autonomic symptoms 0 1 2 3 4
Dry mouth, flushing, pallor, tendency to sweat, giddiness, tension
headache, raising of hair.
14 Behavior at interview 0 1 2 3 4
Fidgeting, restlessness or pacing, tremor of hands, furrowed brow,
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Appendix KJOURNAL AUTHOR INSTRUCTIONS 
 
SOUTH AFRICAN MEDICAL JOURNAL AUTHOR INSTRUCTIONS 
All manuscripts and correspondence to: 
The Editor South African Medical Journal Private Bag X1 Pinelands 7430 (CT) 
COPYRIGHT 
Material submitted for publication in the South African Medical Journal (SAMJ) 
is accepted provided it has not been published elsewhere. Copyright forms 
will be sent with acknowledgement of receipt and the SAMJ reserves 
copyright of the material published. 
The SAMJ does not hold itself responsible for statements made by the 
authors. 
AUTHORSHIP 
All named authors must give consent to publication. Authorship should be 
based only on substantial contribution to: (i) conception, design, analysis and 
interpretation of data; (ii) drafting the article or revising it critically for important 
intellectual content; (iii) final approval of the version to be published. All three 
of these conditions must be met (Uniform requirements for manuscripts 
submitted to biomedical journals; www.icmje.org/index.html). 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any 
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PROTECTION OF PATIENT RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, 
photographs, and pedigrees unless the information is essential for scientific 
purposes and the patient (or parent or guardian) gives informed written 
consent for publication. Informed consent for this purpose requires that the 
patient be shown the manuscript to be published. (www.icmje.org) 
ETHNIC CLASSIFICATION 
Work that is based on or contains reference to ethnic classification must 
indicate the rationale for this. 
MANUSCRIPTS 
Short items are more likely to appeal to our readers and therefore to be 
accepted for publication. Please provide a word count for all submissions. 
Original articles of 3 000 words or less, with up to 6 tables or illustrations, 
should normally report observations or research of relevance to clinical 
medicine. References should preferably be limited to no more than 15. 
Short reports or scientific letters, which include case reports, side effects of 
drugs and brief or negative research findings should be 1000 words or less, 
with 1 table or illustration and no more than 6 references. 
Editorials, Opinions, Issues in Medicine, etc. should be about 800 words 
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Review articles are rarely accepted unless invited. 
Letters to the editor, if intended for the correspondence column, should be 
marked 'for publication', signed by all authors and presented in triple spacing. 
Letters should be no longer than 400 words with only one illustration or table. 




• Please send your manuscript on disc accompanied by three printouts, in 
triple spacing, with wide margins and paginated.  
• Research articles should have a structured abstract not exceeding 250 
words (50 for short reports) comprising: Objectives, Design, Setting, 
Subjects, Outcome measures, Results and Conclusions.  
• Refer to articles in recent issues for guidance on the presentation of 
headings and subheadings.  
• Abbreviations should be spelt out when first used in the text and thereafter 
used consistently.  
• Scientific measurements should be expressed in SI units except: blood 
pressure should be given in mmHg and haemoglobin values in g/dl.  
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1. Figuresconsistofallmaterialthatcannotbesetintype,suchasphotographs and 
line drawings.  
2. Tablesandlegendsforillustrationsshouldappearonseparatesheetsand should 
be clearly identified.  
3. Linedrawingsshouldbearrangedtoconserveverticalspace.Notethat reduction 
to 80 mm for a single column or 170 mm for double columns should not 
render lettering illegible. Explanations should be included in the legend 
and not on the figure itself.  
4. Figurenumbersshouldbeclearlymarkedonthebackofprintsandthetopof 
illustrations should be indicated.  
 
5. Ifanytablesorillustrationssubmittedhavebeenpublishedelsewhere, written 
consent to republication should be obtained by the author from the 
copyright holder and the author(s).  
6. Alimitednumberofillustrationsarefreeatthediscretionoftheeditor.Colour 
illustrations are encouraged but are charged to the author. A quote will 
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listed at the end of the article in numerical and not in alphabetical order. 
Authors are responsible for verification of references from the original 
sources. 
References should be set out in the Vancouver style and approved 
abbreviations of journal titles used; consult the List of Journals in Index 
Medicus for these details. 
Names and initials of all authors should be given unless there are more than 
six, in which case the first three names should be given followed by et al. First 
and last page numbers should be given. 
Journal references should appear thus: 
 
 
• Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975: 
96-101.  
• Weinstein L, Swartz MN. Pathogenic properties of invading 
microorganisms. In: Sodeman WA jun, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 
1974: 457-472.  
 
 
Manuscripts accepted but not yet published can be included as references 
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Unpublished observations and personal communications may be cited in 
the text, but not in the reference list 
GALLEY PROOFS 
Galley proofs will be forwarded to the author before publication and if not 
returned within 2 weeks will be regarded as approved. Pleas note that 
alterations to typeset articles are costly and will be charged to the authors. 
CHANGES OF ADDRESS 
Please notify the Editorial Department of any address changes so that proofs 
and invoices may be mailed without delay. 
REPRINTS 
An order form for reprints, with a price list, will be sent to the author as soon 
as an article has been placed. 
CPD POINTS 
Authors can earn up to 15 CPD points for published articles. Certificates will 
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